Alzheimer's Disease Education and Referral Center

Search for Clinical Trials

Your Search Identified 107 Trial(s):

  • 1. 4 Repeat Tauopathy Neuroimaging Initiative

    Purpose: To identify the best methods for tracking and analyzing progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) over time.

  • 2. AC-1204 for Mild to Moderate Alzheimer's Disease

    Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.

  • 3. ADvance Deep Brain Stimulation in Patients with Mild Probable Alzheimer's Disease

    Purpose: To evaluate the safety of deep brain stimulation of the fornix (DBS-f) in people with mild Alzheimer's disease.

  • 4. Aerobic Exercise in Early Alzheimer's Disease

    Purpose: To test aerobic exercise as a possible treatment for people with early-stage Alzheimer's disease.

  • 5. Aerobic Exercise Training in Mild Cognitive Impairment

    Purpose: To find out whether regulation of brain blood flow is altered in patents with mild cognitive impairment (MCI) when compared with healthy elderly individuals and to determine whether exercise training improves brain blood flow and brain function in patients with MCI.

  • 6. Albumin and Immunoglobulin in Alzheimer's Disease

    Purpose: To evaluate changes in cognition, functioning, and behavior in people with mild to moderate Alzheimer's disease who undergo an experimental infusion treatment.

  • 7. Alzheimer's Biomarkers in African Americans

    Purpose: To determine the influence of Alzheimer's disease and vascular disease on memory and aging in African Americans through biomarkers.

  • 8. Alzheimer's Disease Genetics Study

    Purpose: To identify the genes that are responsible for causing Alzheimer's disease by collecting genetic material from families with multiple members diagnosed with Alzheimer's disease.

  • 9. Alzheimer's Disease Multiple Intervention Trial

    Purpose: To improve functioning among older adults with Alzheimer's disease by comparing a control group receiving best practices primary care with an intervention group receiving best practice primary care plus a home-based occupational therapy intervention.

  • 10. Alzheimer's Prevention Through Exercise

    Purpose: To learn about the possible benefits of aerobic exercise for individuals at risk of developing Alzheimer's disease.

  • 11. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)

    Purpose: To test whether an anti-amyloid investigational drug, solanezumab, can slow memory and cognitive decline in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia.

  • 12. Arterial Spin Labeling (ASL) MRI for Cognitive Decline

    Purpose: To determine the value of arterial spin labeling magnetic resonance imaging, a measure of blood flow to the brain, in finding the cause of cognitive decline in people with mild cognitive impairment.

  • 13. Aspirin in Reducing Events in the Elderly (ASPREE)

    Purpose: To examine whether the potential benefits of low-dose aspirin outweigh the risks in people over age 70.

  • 14. AVP-923 for Treatment of Agitation in Alzheimer's Patients

    Purpose: To evaluate the safety, tolerability, and efficacy of AVP-923 (dxtromethorphan/qinidine) for the treatment of agitation in people with Alzheimer's disease.

  • 15. BAN2401 for Early Alzheimer's Disease

    Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.

  • 16. BIIB037 in Prodromal or Mild Alzheimer's Disease

    Purpose: To evaluate the safety and tolerability of BIIB037 in people with prodromal or mild Alzheimer's disease.

  • 17. Bisnorcymserine in Healthy Adult Volunteers

    Purpose: To test the safety and action of the drug bisnorcymserine in healthy older volunteers.

  • 18. Brain Alterations and Cognitive Impairment in Older Adults with Heart Failure

    Purpose: To study the relationship between brain MRI results and cognitive impairment in older adults with heart failure.

  • 19. Brexpiprazole for Agitation in Alzheimer's Dementia

    Purpose: To assess the efficacy of the experimental drug brexpiprazole in people with agitation due to Alzheimer's dementia.

  • 20. Carvedilol in Alzheimer's Disease

    Purpose: To determine whether carvedilol treatment is associated with improvement in Alzheimer's disease compared to a placebo.

  • 21. Cataract Removal and Alzheimer's Disease

    Purpose: To determine if cataract removal will improve the quality of life, vision, and cognition in people with Alzheimer's disease.

  • 22. Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

    Purpose: To standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden.

  • 23. Coconut Oil for Alzheimer's Disease

    Purpose: To determine the efficacy of coconut oil as a possible treatment for mild to moderate Alzheimer's disease.

  • 24. Cognitive Benefits of Aerobic Exercise Across the Age Span

    Purpose: To test the hypothesis that aerobic exercise leads to improved cognitive function.

  • 25. Comparative Research of Alzheimer's Disease Drug (COMET-AD)

    Purpose: To compare the effectiveness of approved medications for treating Alzheimer's disease in participants from real-world memory care clinics.

  • 26. Curcumin and Yoga Therapy for Mild Cognitive Impairment

    Purpose: To test the clinical benefits of curcumin, a compound isolated from turmeric root, and a yoga-based physical exercise program in individuals with early memory problems.

  • 27. Curcumin Study (18 months)

    Purpose: To study the effects of the dietary supplement curcumin on cognitive decline and abnormal amyloid protein in the brain.

  • 28. Cycling Exercise for Treating Alzheimer's Disease

    Purpose: To investigate the effects of a cycling exercise program on cognition and hippocampal volume in older adults with Alzheimer's disease.

  • 29. Dominantly Inherited Alzheimer Network (DIAN)

    Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

  • 30. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU)

    Purpose: To assess the safety, tolerability, and biomarker efficacy of gantenerumab and solanezumab in individuals who have a genetic mutation for autosomal-dominant Alzheimer's disease.

  • 31. Educational Video to Improve Nursing Home Care in End-Stage Dementia

    Purpose: To determine the impact of an educational video for professional caregivers on the care of nursing homes residents with advanced dementia compared with the usual care.

  • 32. Effect of NeuroAD on Cognitive Function in Alzheimer's Disease

    Purpose: To test the effect of NeuroAD, a noninvasive device that delivers magnetic stimulation to the brain, on cognition in people with Alzheimer's disease.

  • 33. Effects of a Lutein Supplement on Cognitive Function

    Purpose: To determine the effects of taking lutein, a dietary supplement, on cognition in adults of all ages.

  • 34. Effects of Aging and Estrogen on Memory and Cognition

    Purpose: To examine the impact of aging on functional changes induced by estrogen in parts of the brain associated with memory

  • 35. Effects of Anesthesia on Cognition and Alzheimer's Disease Biomarkers

    Purpose: To evaluate the effects of surgical anesthesia on cognition and certain Alzheimer's disease biomarkers in older adults who undergo surgery.

  • 36. Effects of Atomoxetine in Mild Cognitive Impairment

    Purpose: To find out if atomoxetine causes a change in the biomarkers (substances that may indicate the presence of a disease) in the cerebrospinal fluid of people diagnosed with mild cognitive impairment.

  • 37. Effects of Brain Beta-Amyloid on Postoperative Cognition

    Purpose: To determine if the presence of beta-amyloid plaques in the brains of non-demented patients before hip or knee replacement surgery predicts cognitive decline after surgery.

  • 38. Effects of Donepezil Measured by Functional MRI

    Purpose: To examine the sensitivity of functional MRI to detect brain changes in healthy older adults at genetic risk for Alzheimer's disease who take donepezil (Aricept).

  • 39. Effects of Fruitflow-II and Resveratrol on Memory, Fitness, and Cerebral Blood Flow

    Purpose: To determine if Fruitflow-II (a tomato extract), resveratrol (a compound found in some foods), alone or in combination, can effectively treat memory problems in older adults with memory impairment.

  • 40. Effects of Simvastatin on Biomarkers

    Purpose: To test simvastatin to see if it produces beneficial changes in Alzheimer's-related proteins found in cerebrospinal fluid.

  • 41. ELND005 for Agitation and Aggression in Alzheimer's Disease

    Purpose: To determine whether ELND005 is effective in treating symptoms of agitation and aggression in people with Alzheimer's disease.

  • 42. Enhancing Spatial Navigation with Noninvasive Brain Stimulation

    Purpose: To test the effect of noninvasive brain stimulation on older adults' ability to navigate.

  • 43. EVP-6124 for Treating Alzheimer's Disease

    Purpose: To evaluate the safety and efficacy of EVP-6124 as a potential treatment for mild to moderate Alzheimer's disease.

  • 44. Exendin-4 for the Treatment of Alzheimer's Disease

    Purpose: To determine the safety and effectiveness of twice daily administration of Exendin-4 as a treatment for early-stage Alzheimer's disease or mild cognitive impairment.

  • 45. Exercise and Cognitive Training to Improve Cognition in People with Heart Failure

    Purpose: To test the effects on cognition of a combined exercise and cognitive training program in people with heart failure.

  • 46. Exercise, Age-Related Memory Decline, and Hippocampal Function

    Purpose: To test the hypothesis that aerobic exercise leads to increased blood volume in the brain, specifically in the dentate gyrus of the hippocampus.

  • 47. Fitness, Aging, and Stress Study for Dementia Caregivers

    Purpose: To determine whether an aerobic exercise program will alter markers of immune cell aging, improve blood pressure, and decrease psychological distress in caregivers of people with Alzheimer's disease.

  • 48. Gantenerumab for Mild Alzheimer Disease

    Purpose: To evaluate the efficacy and safety of the experimental drug gantenerumab as a possible treatment for people with mild Alzheimer disease.

  • 49. Genetic Characterization of Dementia

    Purpose: To study genetic influences on dementia.

  • 50. Genetic Characterization of Movement Disorders

    Purpose: To learn more about the genetic causes of movement disorders.

  • 51. Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia

    Purpose: To develop small molecule radio-labeled probes of beta-amyloid to be used with positron emission tomography (PET) for early detection and treatment monitoring of Alzheimer disease.

  • 52. Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia

    Purpose: To examine whether decision support for goals of care can improve the quality of communication, decision-making, and palliative care for nursing home residents with advanced dementia.

  • 53. Hispanic Caregiver Intervention Effectiveness Study

    Purpose: To compare two dementia caregiver interventions to determine which is most effective for Hispanic caregivers in New York City.

  • 54. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders

    Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.

  • 55. HT-0712 for Age-Related Memory Impairment

    Purpose: To see if the experimental drug HT-0712 improves memory and cognitive performance in people with mild age-related memory impairment.

  • 56. Human Brain Antioxidants During Oxidative Stress

    Purpose: To evaluate the level of two antioxidants in the brain as humans with and without Alzheimer's disease get older.

  • 57. Imaging of Cognition, Learning, and Memory in Aging

    Purpose: To study how the brain functions when it performs explicit memory tasks and how this changes as a function of aging.

  • 58. Improving Dementia Caregiver Sleep and the Effect on Heart Disease Biomarkers

    Purpose: To determine whether a combined intervention of a nighttime home monitoring system and cognitive-behavioral therapy for insomnia is effective in improving sleep in dementia caregivers who arise at night.

  • 59. Indiana University Dementia Screening Trial

    Purpose: To assess the harms and benefits of screening for dementia, compared to no screening for dementia, among older adults in a primary care setting.

  • 60. Influence of Fitness on Brain and Cognition

    Purpose: To examine the effect of aerobic fitness training on older adults' cognition, brain structure, and brain function.

  • 61. ITI-007 in Individuals with Dementia and Healthy Volunteers

    Purpose: To test the safety and efficacy of the drug ITI-007 in older adults with dementia and in healthy volunteers.

  • 62. Language in Primary Progressive Aphasia

    Purpose: To further define the neurological and linguistic deterioration in primary progressive aphasia.

  • 63. Lidocaine for Neuroprotection During Cardiac Surgery

    Purpose: To see if the drug lidocaine can prevent cognitive decline after heart surgery.

  • 64. Living with Frontotemporal Dementia

    Purpose: To better understand the experience of people with frontotemporal dementia and their caregivers in order to develop better therapies.

  • 65. Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil

    Purpose: To test the drug Lu AE58054 as an add-on therapy to donepezil for people with mild to moderate Alzheimer's disease.

  • 66. LY3002813 for Mild Cognitive Impairment and Alzheimer's Disease

    Purpose: To examine the safety and efficacy of the experimental drug LY3002813 in people with mild cognitive impairment or mild to moderate Alzheimer's disease.

  • 67. MEDI1814 for Mild to Moderate Alzheimer's Disease

    Purpose: To assess the safety and efficacy of the drug MEDI1814 in people with mild to moderate Alzheimer's disease.

  • 68. Memory and Thinking Problems in Older Adults After Surgery

    Purpose: To examine if and how brain scans can predict decline in memory and executive functioning in older adults after total knee replacement surgery.

  • 69. Memory Consolidation in Obstructive Sleep Apnea

    Purpose: To test the use of continuous positive airway pressure (CPAP) to reverse some or all memory deficits in people with obstructive sleep apnea.

  • 70. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

    Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.

  • 71. Mild Cognitive Impairment in Breast Cancer

    Purpose: To study how women undergoing breast cancer treatment may develop brain changes related to the development of mild cognitive impairment.

  • 72. MK-7622 in People with Alzheimer's Disease Taking Donepezil

    Purpose: To test the efficacy and safety of MK-7622 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.

  • 73. MK-8931 for Amnestic Mild Cognitive Impairment

    Purpose: To assess MK-8931 as a possible treatment for amnestic mild cognitive impairment due to Alzheimer's disease.

  • 74. MK-8931 for Mild to Moderate Alzheimer's Disease

    Purpose: To assess the efficacy and safety of MK-8931 as a possible treatment for Alzheimer's disease.

  • 75. Natural History of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Purpose: To characterize the natural history of disease in people who carry a repeat expansion in the C9ORF72 gene, which causes amyotrophic lateral sclerosis and frontotemporal dementia.

  • 76. Neuroimaging in Frontotemporal Dementia

    Purpose: To track changes over time among individuals with frontotemporal dementia (FTD) in the brain using imaging and other biomarkers and to compare the utility of different kinds of images.

  • 77. Nuedexta for Treating Pseudobulbar Affect in Alzheimer's Disease

    Purpose: To test the safety and effectiveness of the drug Nuedexta (dextromethorphan/quinidine) as a treatment for pseudobulbar affect in people with Alzheimer's disease.

  • 78. Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Older Adults

    Purpose: To determine if a worsened sense of smell can identify older people who might benefit from treatment with the Alzheimer's drug donepezil.

  • 79. Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

    Purpose: To determine if difficulty with the sense of smell can predict conversion from mild cognitive impairment to Alzheimer's disease and track response to donepezil therapy.

  • 80. Omega 3 Polyunsaturated Fatty Acid for Vascular Cognitive Aging

    Purpose: To determine whether taking an omega 3 polyunsaturated fatty acid can promote brain health in cognitively normal older adults at risk for dementia.

  • 81. PET Imaging Agent [18F]NAV4694 for Detecting Cerebral Beta-Amyloid

    Purpose: To determine the efficacy and safety of the brain imaging agent [18F]NAV4694 PET.

  • 82. PET Imaging with 18F-AV-1451

    Purpose: To evaluate the characteristics of the brain imaging agent 18F-AV-1451 in cognitively healthy volunteers and in people with mild cognitive impairment or Alzheimer's disease.

  • 83. PET Imaging with [18F]NAV4694 for Predicting Progression to Alzheimer's

    Purpose: To determine whether brain imaging with the agent [18F]NAV4694 can distinguish older adults with mild cognitive impairment who progress to Alzheimer's dementia from those who do not.

  • 84. PET Imaging with [18F]XTRA

    Purpose: To test the ability of the imaging agent [18F]XTRA to detect early brain changes in neurodegenerative diseases such as Alzheimer's.

  • 85. PF-05212377 for People with Alzheimer's Disease and Neuropsychiatric Symptoms

    Purpose: To evaluate safety and efficacy of the experimental drug PF-05212377 in people with mild to moderate Alzheimer's disease and neuropsychiatric symptoms who take donepezil.

  • 86. Pharmacological Management of Delirium (PMD)

    Purpose: To develop and test the feasibility of using a specific pharmacological protocol to reduce delirium among older adults in the intensive care unit.

  • 87. Physical Activity Levels and Brain Structure in Mild Cognitive Impairment

    Purpose: To examine the relationship between physical activity levels, brain structure, and memory function in adults with mild cognitive impairment (MCI).

  • 88. PhytoSERMs for Menopause Symptoms and Age-Associated Memory Decline

    Purpose: To evaluate the safety and efficacy of a soy-based dietary supplement, phytoSERM, for hot flashes and age-associated memory loss.

  • 89. Pomegranate Extract and Memory

    Purpose: To study whether pomegranate extract benefits cognitive abilities in middle-aged and older people without dementia.

  • 90. Pomegranate Juice and Memory

    Purpose: To determine if drinking pomegranate juice benefits cognitive abilities in middle-aged and older adults without dementia.

  • 91. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

    Purpose: To study the effectiveness of prazosin treatment for people with Alzheimer's disease or a related dementia who have difficult behaviors.

  • 92. Prediction of Mild Cognitive Impairment and Pioglitazone to Delay Its Onset

    Purpose: To develop a biomarker that predicts the risk of mild cognitive impairment due to Alzheimer's disease and to test the drug pioglitazone to delay the onset of MCI.

  • 93. Preventing Cognitive Decline in African Americans with Mild Cognitive Impairment

    Purpose: To determine whether increasing participation in cognitive, physical, and/or social activities prevents cognitive decline in older African Americans with mild cognitive impairment (MCI).

  • 94. Progress of Mild Alzheimer's Disease with Solanezumab

    Purpose: To determine if the drug solanezumab will slow cognitive and functional decline in older adults with mild Alzheimer's disease.

  • 95. Reducing Disabilities in Alzheimer's Disease Through Community-Based Services

    Purpose: To test implementation of a program to help older adults with dementia remain physically and mentally healthy through Area Agencies on Aging.

  • 96. Retaining Cognition While Avoiding Late-Life Depression (RECALL)

    Problem: To test Problem Solving Therapy as a way to prevent major depression in people with mild cognitive impairment.

  • 97. Riluzole for Mild Alzheimer's Disease

    Purpose: To test the safety and effectiveness of the drug riluzole for treating mild Alzheimer's disease.

  • 98. Screening and Evaluation of Patients with Signs and Symptoms of Alzheimer's Disease

    Purpose: To determine whether a person meets the eligibility criteria to participate in an Alzheimer's disease research study.

  • 99. Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI)

    Purpose: To investigate the relationship between changes in the ability to manage finances and brain perfusion (blood flow in the brain) and to discover whether changes in financial capacity are better predicted by neuropsychological tests or by an experimental brain scan.

  • 100. Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease, and Controls

    Purpose: To document the loss of sociomoral emotions (like empathy, guilt, and embarrassment) in patients with behavioral variant frontotemporal dementia.

  • 101. Systolic Blood Pressure Intervention Trial: Memory and Cognition in Decreased Hypertension (SPRINT-MIND)

    Purpose: To determine whether intensive blood pressure lowering will reduce the incidence of all-cause dementia, reduce the decline of global cognitive function in key specific domains, and show changes in brain structure.

  • 102. Tailored Activity Program-VA

    Purpose: To test the efficacy of the Tailored Activity Program, a patient-centric intervention designed to reduce the burden of neuropsychiatric symptoms in veterans with dementia who live at home with family caregivers.

  • 103. TRx0237 for Mild Alzheimer's Disease

    Purpose: To determine the safety and efficacy of the experimental drug TRx0237 to treat people with mild Alzheimer's disease.

  • 104. TRx0237 to Treat Behavioral Variant Frontotemporal Dementia

    Purpose: To test the safety and efficacy of TRx0237 as a treatment for behavioral variant frontotemporal dementia.

  • 105. Two Interventions for Early-Stage Dementia

    Purpose: To compare the impact of an exercise program and a social-activity program for people with early-stage dementia and their caregivers.

  • 106. VA Cultivating Access to Resources, Education, and Skills for Dementia Caregivers (VA CARES)

    Purpose: To study the effects of an education and skill-building intervention on family caregivers of veterans with dementia.

  • 107. Walking Intervention, Cognitive Remediation, and Mild Cognitive Impairment

    Purpose: To determine the effects of cognitive remediation training and walking on cognition and gait in the elderly.

  • Return to AD Clinical Trials Search Results

    Return to AD Clinical Trials Home

    Refine Your Search

    Type in a word or phrase such as drug name,
    disease stage, or trial name
    Input a city and state or zip code
    Enter the distance in number of miles from the location
    (default is 50)
    Age of the participant